Short Interest in Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Increases By 88.8%

by · The Cerbat Gem

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC – Get Free Report) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 83,765 shares, a growth of 88.8% from the June 15th total of 44,358 shares. Approximately 8.4% of the company’s stock are short sold. Based on an average daily trading volume, of 30,721 shares, the days-to-cover ratio is presently 2.7 days.

Virtus LifeSci Biotech Clinical Trials ETF Stock Down 3.7%

Shares of Virtus LifeSci Biotech Clinical Trials ETF stock traded down $1.94 during trading on Thursday, hitting $49.91. The company’s stock had a trading volume of 41,454 shares, compared to its average volume of 24,581. Virtus LifeSci Biotech Clinical Trials ETF has a 52 week low of $20.87 and a 52 week high of $54.95. The company has a fifty day simple moving average of $46.34 and a two-hundred day simple moving average of $43.45.

Hedge Funds Weigh In On Virtus LifeSci Biotech Clinical Trials ETF

A hedge fund recently bought a new stake in Virtus LifeSci Biotech Clinical Trials ETF stock. Worth Asset Management LLC bought a new stake in shares of Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 4,093 shares of the company’s stock, valued at approximately $216,000. Worth Asset Management LLC owned about 0.41% of Virtus LifeSci Biotech Clinical Trials ETF as of its most recent filing with the Securities & Exchange Commission.

About Virtus LifeSci Biotech Clinical Trials ETF

(Get Free Report)

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.

See Also